search
Back to results

Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

Primary Purpose

Prosthetic Joint Infection, Vancomycin, Joint Diseases

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Experimental Intraosseous vancomycin 500mg in 250 mL NS
Standard IV administration of vancomycin
Sponsored by
The Methodist Hospital Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Prosthetic Joint Infection focused on measuring total hip arthroplasty, vancomycin, intraosseous vancomycin

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is undergoing a primary total hip arthroplasty
  • Patient gives informed consent to participate in the study.
  • Age Range >18

Exclusion Criteria:

  • Previous surgery on the hip (including hip scopes)
  • BMI above 35
  • Contraindication to receiving vancomycin or cefepime (allergy, medical issue, etc)
  • Inability to locate the greater trochanter or administer the IO infusion
  • Refusal to participate
  • Diabetes
  • Immunocompromised or immunosuppressed patients (HIV, Hep C, End stage renal disease, dialysis, transplant, chemo/radiation treatment in last 6 months, medications).

Sites / Locations

  • Houston Methodist Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

IV administration of vancomycin

IO Vancomycin 500mg in 250 mL NS

Arm Description

Standard IV vancomycin administration protocol.

Experimental Intraosseous administration protocol.

Outcomes

Primary Outcome Measures

Systemic Vancomycin level
vancomycin blood level at time of initiation of closure.

Secondary Outcome Measures

Tissue vancomycin level
at start and end of case.
Femur vancomycin level
at start and end of case.
Acetabulum vancomycin level
at start and end of case.
30-Day Complications
Complications 30 days post surgery i.e. infection.
90-Day Complications
Complications 90 days post surgery i.e. infection

Full Information

First Posted
July 30, 2019
Last Updated
March 13, 2023
Sponsor
The Methodist Hospital Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04042233
Brief Title
Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol
Official Title
Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
December 31, 2019 (Actual)
Primary Completion Date
May 25, 2022 (Actual)
Study Completion Date
September 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Methodist Hospital Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to evaluate a novel vancomycin intraosseous administration protocol vs a standard IV vancomycin administration protocol for primary total hip arthroplasty patients.
Detailed Description
Patients are randomized to one of two groups. GROUP A - Will receive IV antibiotics (cefepime & vancomycin) are started in pre-op approximately 1 hour prior to incision vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 milliliters (mL) normal saline (NS). GROUP B - Will have IV cefepime started in pre-op within 1 hour of incision. Intraosseous (IO) administration of vancomycin (500mg in 250 milliliters NS) will be administered in the OR after sterile prep and draping has occurred. Injection will take place into the greater trochanter (within a pre-specified region). Both Groups will be monitored during surgery and immediately post-operatively for adverse injection reactions (i.e. Red Man Syndrome). Both groups will otherwise follow identical post-operative protocols (including post-operative antibiotic administration). TISSUE SAMPLES Five (5) tissue samples will be taken from each patient, 2 soft tissue samples and 3 bone samples will be taken throughout the course of the procedure. One blood sample will be taken in both groups intraoperatively at the time of initiation of closure. These samples will immediately be sent to a lab for analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prosthetic Joint Infection, Vancomycin, Joint Diseases
Keywords
total hip arthroplasty, vancomycin, intraosseous vancomycin

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
IV administration of vancomycin
Arm Type
Active Comparator
Arm Description
Standard IV vancomycin administration protocol.
Arm Title
IO Vancomycin 500mg in 250 mL NS
Arm Type
Experimental
Arm Description
Experimental Intraosseous administration protocol.
Intervention Type
Drug
Intervention Name(s)
Experimental Intraosseous vancomycin 500mg in 250 mL NS
Intervention Description
500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.
Intervention Type
Drug
Intervention Name(s)
Standard IV administration of vancomycin
Intervention Description
IV antibiotics (cefepime & vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
Primary Outcome Measure Information:
Title
Systemic Vancomycin level
Description
vancomycin blood level at time of initiation of closure.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Tissue vancomycin level
Description
at start and end of case.
Time Frame
1 year
Title
Femur vancomycin level
Description
at start and end of case.
Time Frame
1 year
Title
Acetabulum vancomycin level
Description
at start and end of case.
Time Frame
1 year
Title
30-Day Complications
Description
Complications 30 days post surgery i.e. infection.
Time Frame
From the administration of antibiotics perioperatively to 30 days post op.
Title
90-Day Complications
Description
Complications 90 days post surgery i.e. infection
Time Frame
From the administration of antibiotics perioperatively to 90 days post op.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is undergoing a primary total hip arthroplasty Patient gives informed consent to participate in the study. Age Range >18 Exclusion Criteria: Previous surgery on the hip (including hip scopes) BMI above 35 Contraindication to receiving vancomycin or cefepime (allergy, medical issue, etc) Inability to locate the greater trochanter or administer the IO infusion Refusal to participate Diabetes Immunocompromised or immunosuppressed patients (HIV, Hep C, End stage renal disease, dialysis, transplant, chemo/radiation treatment in last 6 months, medications).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Terry A Clyburn, MD
Organizational Affiliation
The Methodist Hospital Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Houston Methodist Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

We'll reach out to this number within 24 hrs